India's Poly Medicure Setting Up 2 Plants as Demand Rise: MD

The company adapted to pandemic challenges by innovating new products like test kits and face masks. They saw growth in international demand, especially in the renal space, and are investing in new manufacturing plants. The focus is on infection prevention products, with plans to expand both domestically and internationally. Vaccination efforts are underway, and the company is optimistic about future demand. However, regulatory challenges in global markets pose a bottleneck.

What strategies did the company implement to stay in business during the pandemic?

How did the demand for renal products change during the pandemic?

What are the company's plans for investments overseas?

How much is the Indian government planning to invest in healthcare infrastructure?

What new products is the company focusing on to reduce infections in hospitals?

What is the company's outlook on the future demand for their products post-COVID?

What challenges does the company face in terms of regulatory frameworks?